Skip to main content
. 2023 Feb 10;25(3):127. doi: 10.3892/ol.2023.13713

Figure 3.

Figure 3.

Comparison of positivity rates for CEA + CA19-9 + p53-Ab combination with that for CEA + CA19-9 + p53-Ab + s-JMJD6-Abs among patients with colorectal cancer according to the tumor stage. The P-values were calculated by Fisher's exact probability test. Combinatory use of all four markers significantly increased the positive rate than the combinatory use of CEA, CA19-9, and p53-Ab. **P<0.01, *P<0.05. CEA, carcinoembryonic antigen; CA19-9, carbohydrate antigen 19-9; s-JMJD6-Abs, serum antibodies against JMJD6.